Core Viewpoint - The announcement indicates that Xuanzhu Biotech-B (02575) has successfully included its self-developed innovative drug, Pirlosil, in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025, which will take effect on January 1, 2026 [1] Group 1 - The inclusion of Pirlosil (brand name: Xuanyuening) in the 2025 National Basic Medical Insurance Directory will enhance its affordability and accessibility for patients [1] - This development is expected to promote the market penetration and increase the sales scale of the drug, positively impacting the company's long-term operational growth [1] - The company plans to actively cooperate in implementing the insurance policy, continue hospital access initiatives, expand core markets, and increase market coverage to improve patient access to medication [1]
轩竹生物-B：创新药轩悦宁 首次纳入2025国家基本医保目录